In addition, peptidoglycan (PGN), PLK inhibitors (BI 2536, BI 6727, and GSK461364), and propofol (an anesthetic agent) were found to inhibit AKT3 and may be potential candidates for CRC therapeutic regimens57–59. The gene discussed is PLK1; the disease is colorectal carcinoma.